The effect of Nano-curcumin in patients with diabetic hemodialysis

The effects of Nano-curcumin on metabolic status in patients with diabetes on hemodialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150606022562N6

Enrollment

Registered

2019-02-11

Start date

2018-11-06

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group: receiving one 80 mg Nano-curcumin capsule per day for 12 weeks. Intervention 2: Control group: Placebo oral capsule, daily, for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Diabetic hemodialysis patients Aged 18to 80 years

Exclusion criteria

Exclusion criteria: Patients suffering from infectious, inflammatory and malignant diseases. Patients taking curcumin supplements, antioxidant and/or anti-inflammatory supplements within 3 months before participation in the study. subjects receiving immunosuppressive and antibiotics medications.

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Calculation using HOMA formula.	—

Secondary

Measure	Time frame
Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein-cholesterol (HDL-Cholesterol). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High sensitive-C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total Nitric Oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Expression levels of PPAR-? gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Real-Time PCR.;Expression levels of LDLR gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Real-Time PCR Method.;Gluthatione. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Expression levels of TGF-ß gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Real-Time PCR Method.;Fasting blood sugar. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;BUN. Timepoint: At the beginning	—

Measure

Time frame

Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein-cholesterol (HDL-Cholesterol). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;High sensitive-C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total Nitric Oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Expression levels of PPAR-? gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Real-Time PCR.;Expression levels of LDLR gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Real-Time PCR Method.;Gluthatione. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Expression levels of TGF-ß gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: Real-Time PCR Method.;Fasting blood sugar. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;BUN. Timepoint: At the beginning

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereshteh Bahmani

Kashan University of Medical Sciences

bahmani@kaums.ac.ir+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026